Frequently Asked Questions

Get answers to common questions about TULSA-PRO treatment, recovery, and outcomes.

Browse by Category

  • All
  • Treatment
  • Recovery
  • Procedure
  • Insurance
  • Cost
  • Candidacy
  • Outcomes

Is TULSA-PRO FDA authorized for use?

Treatment

Yes. TULSA-PRO received FDA clearance for the treatment of prostate tissue.

 

Clearance and approval are both forms of FDA authorization, granted through different review pathways depending on the type of device. That clearance is based on a review of the device's safety and effectiveness data by the FDA.

Dr. Hong has personally performed 250+ procedures using this cleared technology since bringing it to Arizona.

How long is recovery?

Recovery

Most patients return to normal activity within days and feel fully recovered within two weeks. The minimally invasive nature of TULSA-PRO means significantly shorter recovery times compared to traditional surgical approaches.

Will I need a catheter?

Procedure

Yes, temporarily. Most patients describe it as manageable and short-term. The catheter is typically removed within a few days to weeks, and patients can resume normal activities shortly after.

Is the procedure covered by insurance?

Insurance

Pre- and post-procedure care is often covered. The procedure itself is self-pay. We recommend contacting your insurance provider to understand your specific coverage and benefits.

Is it worth the cost?

Cost

Patients consistently tell us the outcome—health, confidence, peace of mind—was priceless, and the investment in their health and quality of life was invaluable.

Who is a good candidate for TULSA-PRO?

Candidacy

Candidates are typically men with localized prostate cancer who want to preserve sexual function and bladder control. Dr. Hong performs a detailed MRI review to confirm candidacy for each patient.

What are the success rates?

Outcomes

TULSA-PRO has demonstrated strong outcomes in clinical data: up to 98% erectile function preservation in focal ablation patients at 1–2 years (76% for whole-gland treatment), and ~95% average PSA reduction.

 

For comparison, radical prostatectomy preserves erectile function in an estimated 30–70% of men, and radiation in 40–60% — every patient's outcome depends on individual factors like cancer stage, prostate anatomy, and treatment approach, which Dr. Hong reviews in detail during consultation.

How is TULSA-PRO different from other treatments?

Procedure

TULSA-PROTM is the only MRI-guided, whole-gland-enabled ablation therapy. Other minimally-invasive treatments are focal only or do not utilize MRI-precision. TULSA-PROTM combines precision with minimal invasiveness, offering superior outcomes for sexual function and continence compared to surgery or radiation.

Still have questions?

Our team is here to help. Schedule a consultation with Dr. Hong or ask a private question.